• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Integer boosts 2022 revenue projections, cuts earnings outlook

Integer boosts 2022 revenue projections, cuts earnings outlook

July 28, 2022 By Danielle Kirsh

Integer HoldingsInteger (NYSE:ITGR) posted second-quarter results today that beat the overall consensus forecast on Wall Street.

The Plano, Texas–based medical device outsource manufacturer reported profits of $20.8 million, or 62¢ per share, on sales of $350 million for the three months ended July 1, for a bottom-line slide of 29.2% on sales growth of 12.2% compared with Q2 2021.

Adjusted to exclude one-time items, earnings per share were $1.04, 8¢ ahead of The Street, where analysts were looking for sales of $343.57 million.

“Integer delivered second quarter 2022 financial results consistent with our expectations, as sales grew 13% versus the first quarter 2022 and 12% versus prior year. Integer’s associates around the globe remain focused on delivering products for our customers and the patients they serve, while managing the challenges of the ongoing labor and supply chain dynamics,” CEO Joseph Dziedzic said in a news release.

Cardio and vascular sales rose 25% in Q2 and were driven by the company’s Oscor and Aran acquisitions earlier this year. The Oscor acquisition has exceeded Integer’s expectations and has increased the company’s sales outlook by $5 million, to $71 million, according to the company.

Integer expects revenue growth to accelerate in the second half of the fiscal year through new product launches in the electrophysiology, structural heart and neuromodulation markets.

The company upped its revenue projections for the year, saying it expects organic sales growth to be 6% to 8%. It expects $1.37 billion to $1.395 billion in sales for the 2022 fiscal year, slightly ahead of Wall Street expectations. Integer, however, cut its 2022 earnings outlook to $83–93 million from a previous $87–97 million range.

Shares in ITGR were down more than 2% to $68.72 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up slightly.

Filed Under: Business/Financial News, Cardiovascular, Contract Manufacturing, MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: aran biomedical, integer, Oscor

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy